568 related articles for article (PubMed ID: 32291392)
1. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
Han S; Liu Y; Cai SJ; Qian M; Ding J; Larion M; Gilbert MR; Yang C
Br J Cancer; 2020 May; 122(11):1580-1589. PubMed ID: 32291392
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
3. The implications of IDH mutations for cancer development and therapy.
Pirozzi CJ; Yan H
Nat Rev Clin Oncol; 2021 Oct; 18(10):645-661. PubMed ID: 34131315
[TBL] [Abstract][Full Text] [Related]
4. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.
Romanidou O; Kotoula V; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(5):421-436. PubMed ID: 30194083
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutations in gliomas: when an enzyme loses its grip.
Frezza C; Tennant DA; Gottlieb E
Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
[TBL] [Abstract][Full Text] [Related]
7. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
8. [IDH mutation on glioma].
Mukasa A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
[No Abstract] [Full Text] [Related]
9. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
10. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
11. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation in glioma: new insights and promises for the future.
Turkalp Z; Karamchandani J; Das S
JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Kickingereder P; Sahm F; Radbruch A; Wick W; Heiland S; Deimling Av; Bendszus M; Wiestler B
Sci Rep; 2015 Nov; 5():16238. PubMed ID: 26538165
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
15. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
16. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
17. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on IDH Mutation in Diffuse Gliomas.
Su YT; Phan FP; Wu J
Trends Cancer; 2018 Sep; 4(9):605-607. PubMed ID: 30149878
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.
Mellinghoff IK; Chang SM; Jaeckle KA; van den Bent M
Hematol Oncol Clin North Am; 2022 Feb; 36(1):95-111. PubMed ID: 34711457
[TBL] [Abstract][Full Text] [Related]
20. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
